Esculetin attenuates migraine-like pain via CGRP suppression and meningeal mast cell modulation in rat models
Journal of Zhejiang University-SCIENCE B · 2026
DOI: 10.1631/jzus.b2500147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Zhejiang University-SCIENCE B, 2026. Verfasst von Ayca Nur Gonul und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medicine, Bolu Abant Izzet Baysal University, Bolu 14030, Türkiye. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Mast Cells, Umbelliferones, Migraine Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Growing evidence suggests that esculetin, a 5-lipoxygenase inhibitor, has pharmacotherapeutic potential due to its various pharmacological properties, such as potent anti-inflammatory, anti-nociceptive, and γ-aminobutyric acid type A (GABA A ) receptor partial agonist activities. However, the effects of this promising agent on migraine remain unexplored. This study therefore examined the impact of esculetin on relevant mechanisms in migraine-like conditions in rats. The systemic effects of esculetin at three distinct doses (5, 10, and 20 mg/kg) were tested in a nitroglycerin (NTG)-induced migraine model using in vivo experimental sets. The direct action of esculetin on the release of calcitonin gene-related peptide (CGRP) from critical structures of the trigeminovascular system (trigeminal ganglion, trigeminal nucleus, and meningeal afferents) was also tested in ex vivo experimental sets. Sumatriptan was used as a positive control in both sets of experiments. The in vivo results showed that esculetin reduced NTG-induced mechanical hyperalgesia and decreased trigeminal CGRP and cellular Fos proto-oncogene (c-Fos) levels. It also decreased degranulation and meningeal mast cell numbers. The ex vivo results revealed that esculetin reduced NTG-stimulated CGRP release from trigeminovascular explants, with the exception of meningeal explants. Sumatriptan reversed the NTG-induced changes in both experimental sets. Our findings suggest that esculetin exhibits anti-nociceptive activities in experimental migraine conditions, alleviating trigeminovascular CGRP concentrations and the degranulation of meningeal mast cells. Esculetin may thus represent a therapeutic option for relieving migraine headaches, although further research is needed to confirm this.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Medicine, Bolu Abant Izzet Baysal University, Bolu 14030, Türkiye.
- Department of Pediatrics, Faculty of Medicine, Bolu Abant Izzet Baysal University, Bolu 14030, Türkiye.
- Department of Physiology, Cerrahpasa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul 34098, Türkiye. erkan.kilinc@iuc.edu.tr.
Zitieren
APA
Gonul, A. N., Torun, I. E., Kilinc, Y. B., & Kilinc, E. (2026). Esculetin attenuates migraine-like pain via CGRP suppression and meningeal mast cell modulation in rat models. Journal of Zhejiang University-SCIENCE B. https://doi.org/10.1631/jzus.b2500147
Vancouver
Gonul AN, Torun IE, Kilinc YB, Kilinc E. Esculetin attenuates migraine-like pain via CGRP suppression and meningeal mast cell modulation in rat models. Journal of Zhejiang University-SCIENCE B. 2026. doi:10.1631/jzus.b2500147
BibTeX
@article{Gonul2026,
author = {Gonul, Ayca Nur and Torun, Ibrahim Ethem and Kilinc, Yasemin Baranoglu and Kilinc, Erkan},
title = {Esculetin attenuates migraine-like pain via CGRP suppression and meningeal mast cell modulation in rat models},
journal = {Journal of Zhejiang University-SCIENCE B},
year = {2026},
doi = {10.1631/jzus.b2500147}
}
EUVIMED